Presentation is loading. Please wait.

Presentation is loading. Please wait.

Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young.

Published byPauli Korhonen Modified over 5 years ago

Similar presentations

Presentation on theme: "Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young."— Presentation transcript:

1 Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young Children: The Cord Blood Transplantation Study (COBLT) Experience  Donna A. Wall, Shelly L. Carter, Nancy A. Kernan, Neena Kapoor, Naynesh R. Kamani, Joel A. Brochstein, Haydar Frangoul, Rakesh K. Goyal, John T. Horan, Daniel Pietryga, John E. Wagner, Joanne Kurtzberg  Biology of Blood and Marrow Transplantation  Volume 11, Issue 8, Pages (August 2005) DOI: /j.bbmt Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Probability of survival by covariates. A, Overall survival and CINC of relapse. B, Overall survival by remission status. C, Overall survival by original HLA match. D, Overall survival by retrospective HLA match. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Incidence and probability of neutrophil and platelet engraftment and acute and chronic GVHD. A, Hematopoietic recovery. B, Platelet recovery (>50000/μL). C, Acute GVHD grades III/IV. D, Chronic GVHD (limited or extensive). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Maximum toxicity by organ system using the Bearman toxicity scale (by day 42). Relative proportions of patients by grade are shown. With the Bearman toxicity grading scale by day 42, the maximum toxicity experienced in any organ system was 3 (9%) grade 0, 2 (6%) grade I, 17 (53%) grade II, 5 (16%) grade III, and 5 (16%) grade IV. CNS indicates central nervous system; GI, gastrointestinal. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young."

Similar presentations

Umbilical Cord Blood Transplantation in Pediatric Patients with Malignant Diseases J Kurtzberg, SL Carter, JE Wagner, LA Baxter-Lowe, D Wall, N Kapoor,

Umbilical Cord Blood Transplantation in Pediatric Patients with Malignant Diseases J Kurtzberg, SL Carter, JE Wagner, LA Baxter-Lowe, D Wall, N Kapoor,
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children  Daihong.

Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children  Daihong.
Changes in the Clinical Impact of High-Risk Human Leukocyte Antigen Allele Mismatch Combinations on the Outcome of Unrelated Bone Marrow Transplantation 

Changes in the Clinical Impact of High-Risk Human Leukocyte Antigen Allele Mismatch Combinations on the Outcome of Unrelated Bone Marrow Transplantation 
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for.

Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for.
Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.
Total Colony-Forming Units Are a Strong, Independent Predictor of Neutrophil and Platelet Engraftment after Unrelated Umbilical Cord Blood Transplantation:

Total Colony-Forming Units Are a Strong, Independent Predictor of Neutrophil and Platelet Engraftment after Unrelated Umbilical Cord Blood Transplantation:
Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.
KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.
National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants  Robert A. Bray, Carolyn K. Hurley, Naynesh.

National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants  Robert A. Bray, Carolyn K. Hurley, Naynesh.
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation  Claudio G. Brunstein, Effie W. Petersdorf,

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation  Claudio G. Brunstein, Effie W. Petersdorf,
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation  Mats Remberger, Emma.

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation  Mats Remberger, Emma.
Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes  Junya Kanda, Kazuhiro Ikegame,

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes  Junya Kanda, Kazuhiro Ikegame,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H

Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer  Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer  Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Similar presentations

Ads by Google